EW Edwards Lifesciences Corp

  1. Stocks
  2. Healthcare
  3. NYSE: EW

Price (delayed)

$89.79

Market cap

$51.75B

P/E Ratio

51.6

Dividend/share

N/A

EPS

$1.74

Enterprise value

$49.55B

?
Relative Growth: Rel. Growth: 46
Relative Strength: Rel. Strength: 50
Relative Valuation: Rel. Valuation: 17
Relative Profitability: Rel. Profitability: 68

Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, ...

Highlights
EW's revenue is up by 15% year-on-year and by 3.3% since the previous quarter
EW's gross profit is up by 13% year-on-year and by 3.3% since the previous quarter
EW's quick ratio is up by 4.5% since the previous quarter but it is down by 2.3% year-on-year
The net income has plunged by 76% YoY and by 8% from the previous quarter
The company's EPS has shrunk by 75% YoY and by 8% QoQ
Sector: Healthcare
Industry: Medical Devices
Website: http://www.edwards.com
Peers: BSX MMSI LMAT ICUI

Key stats

What are the main financial stats of EW

EW stock price

How has the Edwards Lifesciences stock price performed over time
Intraday
-0.04%
1 week
-1.98%
1 month
6.2%
1 year
10.63%
YTD
5.33%
QTD
-0.74%

Financial performance

How have Edwards Lifesciences's revenue and profit performed over time
Revenue
$6.51B
Gross profit
$5.07B
Operating income
$1.17B
Net income
$1B
Gross margin
77.8%
Net margin
15.4%
The net margin has plunged by 79% YoY and by 11% from the previous quarter
The net income has plunged by 76% YoY and by 8% from the previous quarter
The company's operating margin fell by 28% YoY but it rose by 7% QoQ
The operating income has contracted by 18% YoY but it has grown by 10% from the previous quarter

Price vs fundamentals

How does EW's price correlate with its fundamentals

Growth

What is Edwards Lifesciences's growth rate over time

Valuation

What is Edwards Lifesciences stock price valuation
EW P/E details
P/E
51.6
P/B
4.87
P/S
7.95
EV/EBIT
33.84
EV/EBITDA
29.92
EV/Sales
7.61
The company's EPS has shrunk by 75% YoY and by 8% QoQ
The price to earnings (P/E) is 50% higher than the 5-year quarterly average of 34.4 and 19% higher than the last 4 quarters average of 43.4
The stock's price to book (P/B) is 34% less than its 5-year quarterly average of 7.4 but 3.6% more than its last 4 quarters average of 4.7
The equity has grown by 2.8% since the previous quarter
The P/S is 21% below the 5-year quarterly average of 10.0
EW's revenue is up by 15% year-on-year and by 3.3% since the previous quarter

Efficiency

How efficient is Edwards Lifesciences business performance
EW's return on assets has dropped by 77% year-on-year and by 10% since the previous quarter
Edwards Lifesciences's return on equity has shrunk by 77% YoY and by 8% QoQ
The company's return on sales has shrunk by 71% YoY but it rose by 6% QoQ
The company's return on invested capital has shrunk by 70% YoY but it rose by 8% QoQ

Dividends

What is EW's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EW.

Financial health

How did Edwards Lifesciences financials performed over time
The company's total liabilities rose by 9% YoY and by 5% QoQ
EW's quick ratio is up by 4.5% since the previous quarter but it is down by 2.3% year-on-year
The debt is 93% less than the equity
The equity has grown by 2.8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.